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Abstract
Background: Plasmodium falciparum, the causative agent of human malaria, expresses two aminopeptidases, PfM1AAP and
PfM17LAP, critical to generating a free amino acid pool used by the intraerythrocytic stage of the parasite for proteins
synthesis, growth and development. These exopeptidases are potential targets for the development of a new class of anti-
malaria drugs.
Methodology/Principal Findings: To define the substrate specificity of recombinant forms of these two malaria
aminopeptidases we used a new library consisting of 61 fluorogenic substrates derived both from natural and unnatural
amino acids. We obtained a detailed substrate fingerprint for recombinant forms of the enzymes revealing that PfM1AAP
exhibits a very broad substrate tolerance, capable of efficiently hydrolyzing neutral and basic amino acids, while PfM17LAP
has narrower substrate specificity and preferentially cleaves bulky, hydrophobic amino acids. The substrate library was also
exploited to profile the activity of the native aminopeptidases in soluble cell lysates of P. falciparum malaria.
Conclusions/Significance: This data showed that PfM1AAP and PfM17LAP are responsible for majority of the
aminopeptidase activity in these extracts. These studies provide specific substrate and mechanistic information important
for understanding the function of these aminopeptidases and could be exploited in the design of new inhibitors to
specifically target these for anti-malaria treatment.
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Introduction
Malariaisoneofthedeadliestinfectious diseasesofhumans inthe
world. It is endemic in tropical and subtropical regions, with about
500 million cases of malaria infections and 1.4–2.6 million deaths
each year [1]. Four Plasmodium species commonly infect humans (P.
vivax, P. malariae, P. falciparum and P. ovale) [2,3]. Among them P.
falciparum is of special interest because it is the most lethal and
responsible for most deaths, particularly in pregnant women and
children under the age of five. Drugs such as chloroquine and
mefloquine have played major roles in the treatment of malaria in
the past. However, the spread of drug resistant parasites has meant
that treatment has become increasingly reliant on artemisinin-based
combinationtherapies (ACTs) [4,5]. Accordingly,there is a pressing
need to develop new anti-malarial drugs targeting biochemical
pathways critical for parasite survival and/or transmission.
Malarial parasites digest the infected host’s hemoglobin to
obtain free amino acids [6]. These amino acids are used to
maintain osmotic pressure within infected red blood cells, for
protein synthesis during parasite development and reproduction,
and to set-up a concentration gradient by which rare or absent
amino acids are transported into infected red blood cell from host
serum [7,8]. Two metallo-aminopeptidases M1 alanyl aminopep-
tidase (PfM1AAP) and M17 leucine aminopeptidase (PfM17LAP)
expressed by P. falciparum may be responsible for the terminal steps
of hemoglobin digestion [9,10,11]. It is proposed that these
enzymes hydrolyze small peptides generated by the endoproteo-
lytic digestion of hemoglobin within the parasite’s digestive
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PfM1AAP and PfM17LAP activity by aminopeptidase-specific
inhibitors, such as bestatin, block development of malaria parasites
in vitro and in vivo, suggesting that these enzymes are attractive
targets for the development of a new class of anti-malaria drugs
[12,13,14]. Recently, Valmourougane et al. [15] used the bestatin
scaffold to develop several derivatives and employed these to
explore the active sites of the two malaria enzymes. Subsequently,
Harbut et al. [16] synthesised additional bestatin-based inhibitors
that exhibited specificity for PfM1AAP and PfM17LAP enzymes
and showed that these can block malaria growth in culture, thus
indicating that both enzymes represent targets for anti-malaria
drug design.
Sequence alignment of malaria PfM1AAP and PfM17LAP
aminopeptidases with mammalian orthologs reveals significant
differences in their overall primary structure and in residues that
influence substrate binding (Figure 1). In particular, these data
suggest that the S1 pockets of the malaria enzymes, which accepts
the N-terminal P1 amino acids of a peptide substrate, has different
topology in these enzyme orthologs, which could influence the
binding and catalytic turnover of different classes of amino acids.
Differences between the N-terminal amino acid preferences of
malaria and mammalian enzymes could be exploited in the design
of inhibitors that could kill malaria parasites without inhibition of
their mammalian homologs.
In the present paper, we have examined and compared the
detailed substrate specificities of functionally-active recombinant
forms of PfM1AAP and PfM17LAP. To obtain substrate
fingerprints for each enzyme we employed our recently developed
substrate library consisting of natural and unnatural amino acids
attached to an ACC fluorophore [17]. The information gained
from this library provided extensive activity profiling of functional
recombinant forms of PfM1AAP and PfM17LAP. We also profiled
the general aminopeptidase activity in soluble cell lysates derived
from the 3D7 clone of P. falciparum malaria. Our data show major
differences in the substrate specificity between the two malaria
enzymes that are related to the structure/shape of their active site.
Significant difference was observed between these and the human
aminopeptidase homologs for which we previously determined a
substrate specificity profile [17]. Furthermore, we show that
PfM1AAP and PfM17LAP represent the major aminopeptidase
activity in soluble malaria extracts. This information will be
Figure 1. Multiple sequence alignments of PfM1AAP and PfM17LAP with mammalian orthologs, H: human Homo sapiens, P: pig, Sus
scrofa, R: rat, Rattus norvegicus and X: Plasmodium falciparum. Dashes represent gaps that optimize sequence adjustment. Small or hydrophobic
amino acids are colored in magenta, acidic are red, basic are blue and amino acids with an amine or hydroxyl group are green. Conserved amino acids
are highlighted in gray. Amino acids from active side residues are presented on a black background and those participating in metal binding are
outlined.
doi:10.1371/journal.pone.0031938.g001
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peptidases and elucidation of their function in malaria, and in the
design of specific inhibitory compounds for anti-malarial treatment.
Methods
Materials
All chemicals and solvents were obtained from commercial
suppliers and used without further purification, unless otherwise
stated. Analytical high performance liquid chromatography
(HPLC) analysis used a Beckman-Coulter System Gold 125
solvent delivery module equipped with a Beckman-Coulter System
Gold 166 Detector system by using a Varian Microsorb-MV C18
(25064.8 mm) column. Preparative HPLC analysis used a Beck-
man-Coulter System Gold 126P solvent delivery module equipped
with a Beckman-Coulter System Gold 168 Detector system with a
Kromasil 100-10 C18 (20 mm ID) column (Richard Scientific).
Solvent composition system A (water/0.1%TFA) and system B
(acetonitrile/water 80%/20% with 0.1% of TFA). LC-MS data
were recorded with the aid of the Burnham Medicinal Chemistry
facility using Shimadzu LCMS-2010EV system. The solid phase
substrate library was synthesized using a semiautomatic FlexChem
Peptide Synthesis System (Model 202). Enzymatic kinetic studies
were performed using Spectra MAX Gemini EM fluorimeter
(Molecular Devices) operating in the kinetic mode in 96-well
plates.
Preparation of malaria cell extracts and recombinant
PfM1AAP and PfM17LAP
The intra-erythrocytic stages of 3D7 P. falciparum parasites were
cultured in RPMI containing 10% human serum [18]. Parasites
were lysed from erythrocytes using 0.03% saponin [19] and
extracted by three rounds of freeze-thaw in phosphate-buffered
saline, pH 7.3, prepared as described previously [20]. The
production of recombinant malaria aminopeptidases PfM1AAP
and PfM17LAP in Escherichia coli and their isolation by Ni-chelate
affinity chromatography has been described elsewhere [21,22].
Substrate library screening
To first compare the substrate specificity of the two malarial
aminopeptidases (PfM1AAP and PfM17LAP) an initial screening
of 19 natural amino acids was performed. PfM17LAP was assayed
in 50 mM Tris-HCl, pH 8.0, and was activated with Co
2+ ions at
a final concentration of 1.0 mM. PfM1AAP was assayed in
50 mM Tris-HCl, pH 7.5, without additional metal ions. These
two buffers were made at 25uC and assays were carried out at
37uC. Before adding to the substrate, all enzymes were
preincubated at 37uC for 30 minutes (the enzyme concentration
in these additional screens was between 0.06–0.10 mM). These
screens were carried out using substrate concentrations of 50 mM
and 2.5 mM for PfM1AAP and PfM17LAP, respectively.
A final screening of the 61-membered library of the natural and
unnatural amino acids was then performed: for PfM1AAP screens
the library concentration was 2.5 mM and for PfM17LAP screens
300 nM (total enzyme concentrations in these assays were 0.03–
0.10 mM). The fluorescence signal was monitored continuously
and the wavelength values were following, excitation at 355 nm
and emission at 460 nm. The total time of each assay was between
15–45 minutes. From each single experiment only the linear
portion of progress curve was used to calculate final substrate
specificity represented by RFU/s (production of Relative Fluores-
cence Unit per second) value. Experiments using the entire 61-
membered library were repeated three times and for natural
amino acids sublibrary were repeated twice. The average value
with standard deviations for each substrate were compared with
the best cleaved substrate (100% of specificity) and all data are
presented on plot where x axis represents given fluorogenic
substrate and y axis represents the specificity signified as percent
participation in velocity of the most specific substrate.
Determination of kinetic parameters for best cleaved
substrates (Km,k cat,k cat/Km)
The kinetic parameters of the best substrates were determined
using the above assay conditions. However, before adding to the
substrate, all enzymes were preincubated at 37uC for 30 minutes.
The ACC concentration was calculated by total digestion assay for
each enzyme separately. In each measurement 6 independent
substrates with known concentration were chosen and the average
value was calculated. To measure Km value eight different
concentrations of given substrates and constant enzyme concen-
tration were used. Reaction volume was at 100 mL and enzyme
concentrations were 0.0315 mM and 0.380 mM for PfM1AAP and
PfM17LAP, respectively. To measure kcat/Km value six different
concentrations of given substrates and constant enzyme concen-
tration were used. All experimental conditions were as above. The
fluorescence signal was monitored continuously and the wave-
length value was the following, excitation at 355 nm and emission
at 460 nm. The total time of each assay was between 15–
30 minutes. All experiments were repeated at least three times and
the average value with standard deviation was calculated.
Concentration of DMSO in each experiment was less than 2%
(v/v).
Results
Design of the substrate library
To determine substrate specificity of the enzyme-substrate
complex in the S1 pocket of malaria aminopeptidases, we utilized
a substrate-profiling approach in which a fluorogenic substrate
library containing 61 amino acids was synthesized and used to
profile three mammalian orthologs of the M1 aminopeptidase N
[17]. This library was designed to screen substrate preferences for
19 natural amino acids (to avoid oxidation artifacts we omitted
cysteine) and 42 unnatural amino acids representing a broad
spectrum of side chain substitutions (Figure S1). Most of the
compounds in the library contain an unblocked a-amino group to
satisfy the primary specificity of aminopeptidases.
Additionally, we also synthesized several substrates with diverse
functionalities (for example, a secondary amine derivatives, an a-
hydroxy group, or an amine group in other than the a position)
linked to a fluorophore leaving group (in the P19 position) to
determine how this would influence substrate recognition by
malaria aminopeptidases. It was anticipated that this approach
would provide additional information that could be used to
identify good substrates, design of inhibitors, as well as comparison
of different aminopeptidases. In our present investigation of
substrate specificity, we used functionally-active recombinant
forms of the two P. falciparum aminopeptidases - PfM1AAP and
PfM17LAP (Figure 1) [9,12]. As the fluorophore leaving group we
employed 7-amino-4-carbamoylmethylcoumarin (ACC) because
of its convenience in solid phase synthesis [23].
Recombinant enzyme substrate-specificity results
An initial library screen for each malaria aminopeptidase was
performed to establish optimal screening conditions. For each
enzyme, the best cleaved substrates were chosen and their kinetic
parameters (Km,k cat/Km,k cat) measured. After measurement of
Km we performed a second screen in which the concentration of
Fingerprinting the Malaria Aminopeptidases
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This procedure ensures that substrate cleavage (measured as a
fluorescence signal) is proportional only to kcat/Km and is not
correlated with individual values of Km or kcat. An equal
concentration of the given substrates in each well was obtained
by placing calculated amounts of substrate in the well and then
mixing with enzyme to a total volume of 100 mL. Final substrate
concentrations for the enzymes were as follows: 10 mM for
PfM1AAP (lowest Km=60.8 mM) and 0.3 mM for PfM17LAP
(lowest Km=0.35 mM). It is important to note that the most
challenging library screening was with the PfM17LAP. To obtain
satisfactory fluorescence signals and avoid depletion of substrate at
high enzyme concentration we performed the screen at 0.3 mM,
only slightly below the Km value of the best-cleaved substrate – Igl.
To gain a better insight into substrate specificity of the enzymes
toward natural amino acids, we performed an additional screen at
higher substrate concentration. This did not affect the observed
data because the Km values recorded for these substrates were also
higher, which guaranteed a proportional correlation between
fluorescence signal and kcat/Km:5 0 mM for PfM1AAP (lowest
Km=138.2 mM) and 2.5 mM for PfM17LAP (lowest
Km=3.44 mM).
PfM1AAP aminopeptidase
The natural amino acids preferred by PfM1AAP are leucine
and methionine (Figure 2). Alanine and arginine are also readily
cleaved by this enzyme, but with a slightly lower affinity. Other
amino acids susceptible to hydrolysis by PfM1AAP aminopepti-
dase include Lys, Phe, Tyr, Trp, Gln, Ser and Gly. Negligible
activity was observed for Glu, Asp, Pro, Ile, Thr, Val, His and Asn.
Analysis of the whole library revealed that PfM1AAP exhibits
very broad substrate specificity with this aminopeptidase capable
of cleaving a range of substituents particularly the bulky,
hydrophobic amino acids (Figure 3). The most preferred substrates
were hCha, hPhe and Nle, all of which were cleaved more
efficiently than the best natural amino acid, methionine. A second
series of unnatural amino acids were also hydrolyzed by PfM1AAP
at about 50% of the activity seen for methionine. These were
hArg, Cha, Nva, 4-Cl-Phe, 2-Nal, Igl, hLeu or styryl-Ala.
PfM17LAP aminopeptidase
PfM17LAP exhibited strikingly narrow substrate specificity
toward natural amino acids, particularly in comparison to
PfM1AAP (Figure 2). The most readily accepted substrates are
the hydrophobic amino acids Leu and Trp. Other amino acids
Figure 2. Preferred natural amino acids substrates for recombinant PfM1AAP and PfM17LAP. Initial screening of the 19-membered
natural amino acid library. Enzyme activity was monitored using an fmax multi-well fluorescence plate reader (Molecular Devices) at excitation
wavelength of 355 nm and an emission wavelength of 460 nm. he x-axis represents the abbreviated amino acid names (for full name and structure
see Figure S1). The y-axis represents the average relative activity expressed as a percent of the best amino acid. In the heat map view the most
preferred positions are displayed in bright red, whereas a complete lack of activity is in black, with intermediate values represented by intermediate
shades of red.
doi:10.1371/journal.pone.0031938.g002
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Phe, Met, Thr and Tyr. Cleavage of Ile and His were slightly
above background.
Analysis of the complete substrate library revealed a highly
restricted specificity of PfM17LAP for hydrophobic substrates
(Figure 3). The amino acid derivatives most efficiently cleaved by
PfM17LAP were hPhe and hCha. These two substrates are
cleaved approximately three and five times better than the best-
cleaved natural amino acids Trp and Leu, respectively. Other
amino acid derivatives that are cleaved by PfM17LAP include Igl
and Nle, and less so Nva and hLeu.
To study the distinct substrate differences between PfM1AAP
and PfM17LAP in more detail we determined their kinetic
parameters (Km,k cat,k cat/Km) against a panel of selected natural
and unnatural substrates (Table 1). These studies showed that the
substrates Arg, Ala, HArg, 2-Nal, 3-NO2-Phe and styryl-Ala were
exclusively cleaved by PfM1AAP. By contrast, we did not observe
cleavage of any substrate by PfM17LAP that was not cleaved by
PfM1AAP. For those substrates that both enzymes cleave, the
efficiency or turnover rate (kcat/Km) was always far higher with
PfM1AAP in comparison to PfM17LAP, even for those substrates
most preferred by PfM17LAP (e.g. Leu, hLeu, Phe, hPhe, hCha).
However, the substrate binding affinities, as assessed by Km, for
PfM17LAP were between one or two orders of magnitude lower as
compared to PfM1AAP. These data indicate that the two enzymes
function in milieu of different substrate concentration; PfM1AAP
works more effectively at relatively high substrate concentration
while PfM17LAP functions more efficiently at much lower
substrate concentrations.
Malaria cell lysate substrate specificity results
To understand the nature of the aminopeptidase activity
expressed by malaria parasites we screened our substrate library
with a soluble malaria cell extract derived from the 3D7 clone of P.
falciparum. We employed the substrate library at an arbitrary final
concentration of 5 mM. This concentration was determined in a
preliminary screening test to be sufficient to obtain a good and
linear fluorescence signal (data not shown). No activity was
observed against fluorogenic peptides substrates when lysates of
uninfected erythrocytes were prepared in a similar manner to the
parasite-infected erythrocytes as reported previously [9].
Our data demonstrate that several substrates are efficiently
cleaved by aminopeptidases in the cell lysate (Figure 4). Interest-
ingly, the substrate profile closely represents a combination of
activity of both PfM1AAP and PfM17LAP aminopeptidases. The
most readily cleaved substrates (e.g. Arg, Ala, Leu, Met, hCha)
show a close overlap with those cleaved by either recombinant
enzymes. To validate this observation we performed a library
screen in which the soluble cell lysate was preincubated for
30 minutes with 50 mM hPhe-PO3H2, which we have previously
shown is a potent inhibitor of both PfM1AAP and PfM17LAP
[14,24]. No activity was observed toward any substrate in the
Figure 3. Individual preferences in S1 pocket of PfM1AAP and PfM17LAP enzymes toward natural and unnatural amino acid
substrates. Screening of the 61-membered natural and unnatural amino acid library. Enzyme activity was monitored using an fmax multi-well
fluorescence plate reader (Molecular Devices) at excitation wavelength of 355 nm and an emission wavelength of 460 nm. The x-axis represents the
abbreviated amino acid names (for full name and structure see Figure S1). The y-axis represents the average relative activity expressed as a percent of
the best amino acid. In the heat map view the most preferred positions are displayed in bright red, whereas a complete lack of activity is in black,
with intermediate values represented by intermediate shades of red.
doi:10.1371/journal.pone.0031938.g003
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observed hydrolysis of the substrates by malaria soluble cell lysates
results solely from the two aminopeptidases.
Discussion
Malaria is currently considered one of the most deadly
infectious global diseases of humans, killing approximately 1
million people in sub-Saharan Africa alone each year. New
approaches to overcome the spread of malaria parasites that have
become resistant to currently available drugs are necessary,
particularly the identification of novel drugs targeting metabolic
pathways. The aminopeptidases PfM1AAP and PfM17LAP are
critical to the growth and development of malaria parasites within
the erythrocyte as knockout of either aminopeptidase gene is lethal
to the parasite [11,12], and therefore they are both currently
considered as promising targets for medicinal intervention [12].
The two enzymes are suggested to participate in the final step of
hemoglobin digestion, the main source of nutrient for the parasite,
resulting in the production of single amino acids, which are
Table 1. Kinetic parameters for selected substrates.
Pf M1AAP Pf M17LAP
Km, mMk cat,s
21 kcat/Km,M
21 s
21 Km, mMk cat*10
3,s
21 kcat/Km,M
21 s
21
Ala 240.6610.9 1.05460.154 43796444 not cleaved
Arg 214.3618.5 0.87660.105 40866187 not cleaved
hArg 124.3615.6 1.14460.100 92066507 not cleaved
Leu 140.9612.1 0.86860.111 61596301 30.3261.48 2.62260.077 82.565.2
hLeu 210.8626.6 1.85960.030 881961481 4.05960.017 0.71760.121 176.6615.5
Phe 218.066.2 0.42260.028 19376159 9.26760.356 1.66860.109 180.067.2
hPhe 60.863.1 0.97860.003 1609761754 0.59560.004 0.27760.029 466.3651.3
Met 138.267.9 0.88760.077 64206200 3.44060.297 0.11760.007 34.161.8
Trp 144.4618.7 0.44460.052 30716107 22.9960.686 3.19460.227 139.065.9
Cha 269.8630.8 1.35860.140 50346692 7.77760.520 0.83960.125 107.9613.3
hCha 96.3616.2 1.59260.230 165326431 0.43760.016 0.21160.005 483.2618.3
2-NaI 316.6624.9 0.88460.018 27926248 not cleaved
3-NO2-Phe 131.7619.9 0.14160.026 10726221 not cleaved
Nva 267.167.7 2.78660.228 1042961158 8.48760.310 0.92360.141 108.8613
allyl-Gly 266.7625.2 1.52060.301 57006720 11.3561.89 0.47960.106 42.364.3
IgI 84.766.1 0.49260.032 58116302 0.34260.022 0.15360.006 448.9629
styryl-Ala 192.7610.5 0.93760.154 48646556 not cleaved
Nle 110.1613.6 1.39960.119 1270861180 3.29360.076 0.61860.090 187.8611.8
Comparison of the kinetic parameters (Km,k cat,k cat/Km) of the selected substrates for PfM1AAP and PfM17LAP. The results are presented as mean values with standard
deviation.
doi:10.1371/journal.pone.0031938.t001
Figure 4. Total aminopeptidase activity explored in the 3D7 clone of P. falciparum in the absence (A). Aminopeptidase activity in soluble
malaria parasite extracts was monitored using an fmax multi-well fluorescence plate reader (Molecular Devices) at excitation wavelength of 355 nm
and an emission wavelength of 460 nm. The x-axis represents the abbreviated amino acid names (for full name and structure see Figure S1). The y-
axis represents the average relative activity expressed as a percent of the best amino acid. Note, the addition of the aminopeptidease-specific
inhibitor hPhe-PO3H2 (50 mM) to any of the above experiments completely abrogated cleavage of every substrate, thus confirming that the observed
signal originates only from these enzymes.
doi:10.1371/journal.pone.0031938.g004
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and develop with the host erythrocyte. As much as 70% of the
erythrocyte hemoglobin is degraded suggesting that an efficient
catabolic process is required [6]. However, the aminopeptidases
may also function in the regular catabolic turnover of malaria
proteins or biogenesis of intracellular organelles as the parasite
undergoes recognized stage-specific developments [9,10,24].
Previous studies in the search for phosphonate or phosphinate
compounds that inhibit both PfM1AAP and PfM17LAP resulted
in the selection of several compounds that significantly reduced
development of malaria parasites both in erythrocyte cell culture
and in the murine P. c. chabaudi model of malaria [14,25].
However, since these compounds block the activity of both
enzymes it remains to be determined whether killing is due to
inhibition of one or both enzymes. Harbut et al. [16] recently used
a bestatin scaffold to develop inhibitors that showed a 12–15 fold
specificity for either PfM1AAP or PfM17LAP and demonstrated
that these killed malaria parasites in vitro. The PfM1AAP-specific
inhibitors caused swelling of the malaria digestive vacuole and
disrupted proteolysis of haemoglobin-derived peptides while the
PfM17LAP-specific inhibitors killed malaria parasite prior to the
onset of haemoglobin digestion. These support the idea that
the two enzymes play distinct roles in malaria parasites and that
both can be targeted for anti-malaria drug development [12].
Recently, the high-resolution X-ray crystal structures of both
PfM1AAP and PfM17LAP were determined and revealed large
differences within the S1 pockets of their active sites [19,20]. Both
molecules revealed extensively buried active sites centered around
the essential active site cation(s). However the nature and size of
the S1 pocket varied dramatically. The PfM1AAP S1 pocket is
long and contains acidic residues deep in the pocket, thus forming
an excellent platform for docking amino acids of basic character.
Notably, a polar glutamic acid (Glu
572) residue is located at the
base of the pocket where it would be available to form an ionic
interaction with the side chains of long and basic side chains.
Comparison of bestatin-bound and unbound PfM1AAP structures
also revealed flexibility of polar residues deep within the S1 pocket,
thus possibly providing further adaptability to the shape of the S1
pocket. Valmourougane et al. [15] showed using bestatin-based
inhibitors that the S1 pocket, residues 570–575, is flexible and can
move to accommodate large side chains. Our library-screening
results confirm that PfM1AAP aminopeptidase can cleave a large
variety of amino acids with small or bulky amino acids side chains.
One of the best cleaved are compounds with Arg and hArg, thus
confirming at a mechanistic level the crystal structure data analysis
and predictions. In contrast, the PfM17LAP S1 pocket that
interacts with the substrate P1 residue is a small, narrow and
substantially hydrophobic. Structural analysis suggested that only
hydrophobic amino acids could be tolerated in this binding pocket.
In the bestatin-bound structure, the P1 Phe-like moiety was tightly
packed into the S1 pocket, forming stacking interactions with the
hydrophobic pocket. Analysis of substrate library data for
PfM17LAP confirms predictions from its crystal structure by
showing that this enzyme efficiently cleaves amino acids with bulky
and hydrophobic side chains, while the presence of any
hydrophilic group leads to reduced binding. The size and
hydrophobic nature of this narrow pocket explains the inability
of this enzyme to cleave peptides/proteins after polar residues.
Analysis of the PfM17LAP structure reveals no suitable polar
hydrogen bonding partners at the base of the S1 pocket that could
interact with a charged P1 side chain.
Substrates capable of differentiating between the two malaria
aminopeptidases are Ala, Arg and hArg, a property that can be
applied in the future for the specific monitoring activity of
PfM1AAP in cell lysates as well as for design of specific inhibitors
for this enzyme. On the other hand, both PfM1AAP and
PfM17LAP preferentially recognize and cleave two unnatural
amino acids – hPhe and hCha. Phosphonate derivatives of these
substrates were reported previously as very good inhibitors of
recombinant PfM17LAP and in malaria cell culture experiments,
thus confirming that substrate specificity data can yield useful
information for design of aminopeptidases inhibitors [14,25].
Our previous studies using a restricted number of natural amino
acid derivatives of fluorogenic substrates indicated that the two
aminopeptidases exhibit distinct but overlapping substrate speci-
ficities [9,19]. The availability of our library of 61 individual
fluorogenic substrates in the form of natural and unnatural amino
acids allowed us to perform comparative screens with the
aminopeptidases, PfM1AAP and PfM17LAP. This has given us a
more detailed understanding of the biochemistry of each
PfM1AAP and PfM17LAP, which could enable the future design
of specific substrates and inhibitors of each enzyme. The enzyme
kinetic parameters presented in Table 1 show that the broad-
acting PfM1AAP cleaves all substrates that are also cleaved by the
more restrictive PfM17LAP. Moreover, PfM1AAP cleaves these
substrates with a far greater efficiency, with kcat/Km values in the
region of 40–100 fold higher. Additionally, the Km values obtained
for PfM17LAP are between one or two orders of magnitude lower
than those of PfM1AAP. This further supports the suggestion that
both enzymes may not function together in the same catabolic
pathway and/or in the same cellular compartment. It is most
probable that PfM1AAP functions in a cellular environment where
its substrates are in high concentration. Immunolocation studies
[11,21,26,27] suggest that this could possibly be within or adjacent
to the parasites digestive vacuole where the initial endo- and exo-
proteolytic cleavages of host hemoglobin would generate high
concentrations of peptide substrates. In contrast, PfM17LAP,
which was localized to the cytoplasm of the malaria cell [9,12,21],
could function where it substrates, peptides derived from
hemoglobin or other proteins, are in lower concentration. Because
of its strict specificity for leucine, we have previously suggested that
a prime function of PfM17LAP could be in generating high
intracellular concentrations of leucine that can be exchanged via
specific channels for extracellular isoleucine [28], an essential
amino acid not found in human hemoglobin [9,12].
One of the objectives of this study was to characterize the
aminopeptidase activity of aminopeptidases in malaria extracts
and compare this to the recombinant PfM1AAP and PfM17LAP.
Our data clearly show that PfM1AAP and PfM17LAP are
primarily responsible for the aminopeptidase activity in the soluble
lysates of the 3D7 clone of P. falciparum. There are four types of
methionine aminopeptidases (MetAP) expressed in malaria cells
[29] and we expected that this activity would be particularly
enhanced in the substrate profile of soluble cell lysates compared
to the recombinant PfM1AAP and PfM17LAP. Interestingly, this
was not the case and it is most probable that MetAP activities are
presence at a low level in the soluble lysates, although other
possibilities include that these enzymes are membrane bound. Our
data strongly suggests that both PfM1AAP and PfM17LAP are the
predominant exo-aminopeptidases in the soluble lysates of the
malaria parasites.
In conclusion, we have used a new library of fluorogenic
substrates designed from natural and unnatural amino acids to
define the distinct substrate specificity and kinetic parameters of
two malaria aminopeptidases PfM1AAP and PfM17LAP, potential
targets for new anti-malarials. Aminopeptidase fingerprint of
PfM1AAP overlaps very well with previously published data for
three mammalian (human, rat and pig) orthologs of this enzyme
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enzyme in term of substrate recognition preferences. This suggests
that designing inhibitors that block the activity of the malaria
enzyme without inhibiting the host enzyme will present a major
challenge. However, our results show individual features of each
malaria aminopeptidase in term of binding substrates in S1 pocket
and suggest that compounds that inhibit each enzyme specifically
or together could be synthesized for combination therapies. This
suggestion is supported by the recent results of Valmourougane
et al. [15] and Harbut et al. [16] who designed PfM1AAP- and
PfM17LAP-specific inhibitors using the basic bestatin scaffold,
although these did not show enhanced killing of parasite over
bestatin itself. We have also shown that our library could be
employed for activity profiling of cell extracts from different strains
of malaria. Finally, our analysis can form the basis for future
selection of specific substrates for this group of proteases as well as
for the design of inhibitors, which could further help to answer
questions about their relative importance in malaria development.
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